Trabectedin (ET-743, YondelisTM) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug
Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer
Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels—A pharmacodynamic study
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors : Result of a dose-intensity study
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma
Arsenic trioxide in patients with hepatocellular carcinoma : A phase II trial
Phase II trial of nolatrexed dihydrochloride [ThymitaqTM, AG 337] in patients with advanced hepatocellular carcinoma